WO2026137597 - MUCOSA-BASED NON-INVASIVE GENE THERAPY WITH RECOMBINANT VECTOR
National phase entry is expected:
Publication Number
WO/2026/137597
Publication Date
02.07.2026
International Application No.
PCT/CN2025/080921
International Filing Date
06.03.2025
Title **
[English]
MUCOSA-BASED NON-INVASIVE GENE THERAPY WITH RECOMBINANT VECTOR
[French]
THÉRAPIE GÉNIQUE NON INVASIVE À BASE DE MUQUEUSE AVEC VECTEUR RECOMBINANT
[Chinese]
重组载体基于黏膜的无创基因疗法
Applicants **
SUZHOU ROCROCK NO.1 BIOTECHNOLOGY CO., LTD.
Inventors
YIN, Xiushan
WANG, Min
Priority Data
PCT/CN2024/143559
28.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1674 | |
| EPO | Filing, Examination, Granting | 11440 | |
| Japan | Filing, Examination, Granting | 2152 | |
| South Korea | Filing, Examination, Granting | 2061 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,067
Contact Us
Abstract[English]
The present invention provides a mucosa-based non-invasive gene therapy with a recombinant vector. The recombinant region of the recombinant vector comprises a coding sequence of at least one therapeutic gene. The recombinant vector is administered to the respiratory system, the digestive system, the genitourinary system, and the eyes via the mucosa, for preventing and/or treating a disease.[French]
La présente invention concerne une thérapie génique non invasive à base de muqueuse avec un vecteur recombinant. La région recombinante du vecteur recombinant comprend une séquence codante d'au moins un gène thérapeutique. Le vecteur recombinant est administré au système respiratoire, au système digestif, au système génito-urinaire et aux yeux, par l'intermédiaire de la muqueuse, pour prévenir et/ou traiter une maladie.[Chinese]
本发明提供一种重组载体基于黏膜的无创基因疗法，所述重组载体的重组区域具有至少一个治疗基因的编码序列；其中所述重组载体通过机体黏膜施用至呼吸系统、消化系统、泌尿生殖系统以及眼部，用于预防和/或治疗疾病。